Teva’s AJOVY shows promising results in migraine prevention Phase IV study
New interim analysis from the pan-European PEARL Phase IV study reveals that Teva Pharmaceutical Industries' AJOVY (fremanezumab) has led to a significant reduction in monthly ... Read More
Teva secures FDA approval for Ajovy injection in migraine prevention
Teva Pharmaceutical Industries has achieved a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) approving Ajovy (fremanezumab-vfrm) injection for migraine prevention in ... Read More